BNP Paribas Asset Management
AUTL

BNP Paribas Asset Management’s Autolus Therapeutics AUTL Stock Holding History

BNP Paribas Asset Management’s Portfolio AUTL Stock Details AUTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.38M Hold
3,361,156
– – 0.01% 871
2026
Q1 		$4.64M Hold
3,361,156
– – 0.01% 874
2025
Q4 		$6.69M Buy
+3,361,156
New +$5.16M 0.01% 768

Other funds holding AUTL

MCO
MAK Capital One New York $714M AUM 68.07% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
SP
Syncona Portfolio St Peter Port, Guernsey $26.6M AUM 10.36% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $635M AUM 28.07% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $141B AUM 34.18% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

BNP Paribas Asset Management's AUTL Position: Q2 2026 in Review

BNP Paribas Asset Management held its Autolus Therapeutics (AUTL) position steady in Q2 2026 at 3,361,156 shares worth $5.38M. The position accounts for 0.01% of the portfolio, ranked #871.

BNP Paribas Asset Management first reported a position in AUTL in Q4 2025 and has held it in 3 quarters since. The position peaked at $6.69M in Q4 2025. 84 funds tracked by Wall St. Rank hold AUTL as of Q2 2026.

  • BNP Paribas Asset Management held 3,361,156 shares of Autolus Therapeutics worth $5.38M as of Q2 2026.
  • BNP Paribas Asset Management left its Autolus Therapeutics share count unchanged in Q2 2026.
  • Autolus Therapeutics made up 0.01% of BNP Paribas Asset Management's portfolio in Q2 2026, its #871 holding.
  • BNP Paribas Asset Management first reported a position in Autolus Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • BNP Paribas Asset Management's Autolus Therapeutics position peaked at $6.69M in Q4 2025.
  • 84 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q2 2026.

Based on BNP Paribas Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.